| |
Approaching early development strategically is critical to the later success of a drug candidate. Discover the current challenges and considerations for biotechs to maximize drug development outcomes. +(2)+(2).png)
|
|
Today’s Big NewsJan 13, 2025 |
|
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about packaging innovations and aseptic filling solutions that meet the demands of emerging therapies and ensure product integrity, safety and efficiency. 
|
|
| By Kevin Dunleavy Johnson & Johnson has opened the J.P. Morgan Healthcare Conference with a bang, buying out Intra-Cellular Therapies for $14.6 billion. At $132 per share, J&J paid a 39% premium on Friday’s closing price of Intra-Cellular, a New York City based biotech that develops and markets products for the central nervous system. |
|
|
|
By Fraiser Kansteiner,Zoey Becker,Angus Liu,Kevin Dunleavy,Eric Sagonowsky While the overall volume of pharma and life sciences M&A activity was healthy in 2024 versus historic levels, deals trended toward the smaller side, reducing the total deal value observed for the year. That inclination for large pharma companies to pursue small and mid-sized transactions is likely to persist in 2025, too, analysts at Leerink Partners and PwC have opined. |
By Conor Hale Illumina and Regeneron are taking stakes in health data company Truveta to help fund research that may dwarf previous DNA sequencing projects. |
By Ben Adams,James Waldron,Gabrielle Masson,Darren Incorvaia,Angus Liu It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the year. |
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now. 
|
|
By Nick Paul Taylor Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan Healthcare Conference with a deal to buy Scorpion Therapeutics’ PI3Kα pipeline for up to $2.5 billion. |
By Fraiser Kansteiner,Angus Liu,Ben Adams,Kevin Dunleavy,Zoey Becker,Eric Sagonowsky For the 43rd edition of the JPM conference, Johnson & Johnson stole the spotlight off the bat. But plenty of other company updates are on deck for day 1. |
By Gabrielle Masson In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal cancer asset. |
By Ben Adams Gilead continues its divergence out of its original infectious disease beginnings and into cancer and, now, more deeply than before, into inflammation, penning a major $1.7 billion deal with dermatology specialist Leo Pharma just a few days before the J.P. Morgan Healthcare Conference. |
By Nick Paul Taylor Y-mAbs Therapeutics is parting ways with its chief commercial officer and putting a new hire in charge of the cancer drug Danyelza. The biotech made the changes, which include “a small adjustment” to the commercial team, as part of a rethink that could put 13% of its employees out of work. |
By Fraiser Kansteiner Against the backdrop of poor sales for the company’s COVID-19 shot Spikevax and its recently approved RSV prophylactic mRESVIA, Moderna is “accelerating and expanding” its prior efficiency and prioritization efforts. The company plans to hive off roughly $1 billion from its annual spend in 2025. |
By Conor Hale In an early look at its 2024 earnings, Guardant's $737 million total topped not only Wall Street estimates but its own financial forecast. |
By Nick Paul Taylor What connects a broken windshield, a raccoon infestation and Peyronie’s disease? According to Endo, all three challenges are examples of when people benefit from speaking up and getting recommendations from trusted sources. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we dive into 2024's batch of new FDA drug approvals, highlighting some potential blockbusters and shifts from previous years' lists. |
|
|---|
|
|
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
.+(1).png)
